AG013
Phase 1Biologic
AG013 is one of 35 biologic programs targeting Oral Mucositis. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
132 competitors in Oral Mucositis
#DrugCompanyPhaseTrials
1Afinitor
NovartisPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Duragesic
CCephalon
Phase 3
Bactroban
PPadagis LLC
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Benadryl
PParkedale
Phase 3
Curcumin
Merck & Co.Phase 3
N-Acetyl Cyteien
SStanford University
Phase 3
Zinc Acetate
NNobelpharma
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AG013. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AActoGeniX N.V.